These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 28653329)

  • 1. Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombocythemia.
    Montemayor-Garcia C; Coward R; Albitar M; Udani R; Jain P; Koklanaris E; Battiwalla M; Keel S; Klein HG; Barrett AJ; Ito S
    Transfusion; 2017 Sep; 57(9):2136-2139. PubMed ID: 28653329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.
    Rumi E; Pietra D; Guglielmelli P; Bordoni R; Casetti I; Milanesi C; Sant'Antonio E; Ferretti V; Pancrazzi A; Rotunno G; Severgnini M; Pietrelli A; Astori C; Fugazza E; Pascutto C; Boveri E; Passamonti F; De Bellis G; Vannucchi A; Cazzola M;
    Blood; 2013 May; 121(21):4388-95. PubMed ID: 23575445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation.
    Tao J; Zhang X; Lancet J; Bennett JM; Cai L; Papenhausen P; Moscinski L; Zhang L
    Cancer Genet; 2014; 207(10-12):489-94. PubMed ID: 25453399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MPL-mutated essential thrombocythemia: a morphologic reappraisal.
    Szuber N; Hanson CA; Lasho TL; Finke C; Ketterling RP; Pardanani A; Gangat N; Tefferi A
    Blood Cancer J; 2018 Nov; 8(12):121. PubMed ID: 30459342
    [No Abstract]   [Full Text] [Related]  

  • 7. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia.
    Haider M; Elala YC; Gangat N; Hanson CA; Tefferi A
    Blood Cancer J; 2016 Oct; 6(10):e487. PubMed ID: 27768091
    [No Abstract]   [Full Text] [Related]  

  • 9. Mosaicism due to myeloid lineage restricted loss of heterozygosity as cause of spontaneous Rh phenotype splitting.
    Körmöczi GF; Dauber EM; Haas OA; Legler TJ; Clausen FB; Fritsch G; Raderer M; Buchta C; Petzer AL; Schönitzer D; Mayr WR; Gassner C
    Blood; 2007 Sep; 110(6):2148-57. PubMed ID: 17537994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
    Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
    Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mosaicisms of chromosome 1 at two different stages of ontogenetic development detected by Rh blood group discrepancies.
    Dauber EM; Mayr WR; Hustinx H; Schönbacher M; Budde H; Legler TJ; König M; Haas OA; Fritsch G; Körmöczi GF
    Haematologica; 2019 Mar; 104(3):632-638. PubMed ID: 30237270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
    Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
    Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
    Lieu CH; Shen YJ; Lai WC; Tsai WH; Hsu HC
    J Chin Med Assoc; 2010 Oct; 73(10):530-2. PubMed ID: 21051030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation.
    Rumi E; Passamonti F; Arcaini L; Bernasconi P; Elena C; Pietra D; Brisci A; Arbustini E; Cazzola M; Lazzarino M
    Bone Marrow Transplant; 2010 Apr; 45(4):798-800. PubMed ID: 19734947
    [No Abstract]   [Full Text] [Related]  

  • 15. Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene.
    Liu S; Ye Z; Gao Y; He C; Williams DW; Moliterno A; Spivak J; Huang H; Cheng L
    Stem Cell Res; 2017 Jan; 18():57-59. PubMed ID: 28395806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for CALRity in myeloproliferative neoplasms.
    Cook JR
    Am J Clin Pathol; 2015 May; 143(5):617-9. PubMed ID: 25873492
    [No Abstract]   [Full Text] [Related]  

  • 18. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
    Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
    Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
    Kilpivaara O; Levine RL
    Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New advances in the pathogenesis and therapy of essential thrombocythemia.
    Levine RL; Heaney M
    Hematology Am Soc Hematol Educ Program; 2008; ():76-82. PubMed ID: 19074062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.